KidneyIntelX™ has been

Results you can count on.



of patients are expected to have a low-risk score

Patients are likely to have stable kidney function over the next five years

Follow up at least annually



of patients are expected to have an intermediate-risk score

Patients are at an average risk for progression to ESKD

May need modification and a specialist consultation

Follow-up at least 2x year



of patients are expected to have a high-risk score

Patients at elevated risk for progression to ESKD

Will require aggressive lifestyle changes, medication management and specialist referrals

Plus, real-world evidence demonstrates that

PCPs want this tool.


Percentage of PCPs who would adopt KidneyIntelX to identify adult patients with type 2 diabetes and CKD who are at risk of accelerated kidney function decline


More likely to appropriately prescribe SGLT2 inhibitors (SGLT2i) and angiotensin II receptor blockers (ARB) for their high-risk patients

Nearly 3X

More likely to appropriately refer their high-risk patients to a specialist